Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.10.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Lin Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Key Laboratory for Precisi…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Philadelphia-negative B-cell acute lymphoblastic leukemia (Ph- B-ALL) remains a therapeutic challenge in adults. Cytogenetic abnormalities and measurable residual disease (MRD) are key prognostic markers, but their integration with allogeneic hematopoietic stem cell transplantation (HSCT) is not well defined. MATERIALS AND METHODS: This single-center retrospective study analyzed 368 adult Ph- B-ALL patients, classifying them into 9 cytogenetic subgroups. We evaluated the prognostic effect of high-risk cytogenetics (KMT2A-rearranged, 14q32/IGH, t(1;19)) and MRD status on outcomes, with particular focus on HSCT's modifying role. RESULTS: Without HSCT, patients with high-risk cytogenetics had significantly inferior 3-year survival compared with cytogenetically normal patients (overall survival (OS): 24.3% vs. 56.5%, P < .001; disease-free survival (DFS): 8.3% vs. 41.4%, P < .001). HSCT eliminated these disparities, yielding comparable outcomes between high-risk and normal subgroups (post-HSCT OS 76.9% vs. 70.8%, P = .603). MRD positivity after consolidation independently predicted relapse in nontransplant patients (HR 3.29, 95% CI, 1.31-8.27, P = .012) but not after HSCT. Reduced-intensity conditioning was associated with worse DFS compared with myeloablative regimens (HR 2.51, 95% CI, 1.24-5.10, P = .011). CONCLUSION: Our results support a dual approach: HSCT for patients with high-risk cytogenetics or MRD positivity, and MRD-guided therapy for those not eligible for transplant. These findings reinforce risk-adapted strategies and lay the groundwork for future trials combining genetic and MRD-guided management in Ph- B-ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Maligancies, Hangzhou, Chi…
- School of Medicine, Zhejiang University, Hangzhou, China.
Zitieren
APA
Liu, L., Gu, J., Wang, L., Maleki Goli, M., Ghanad, P., Xu, H., Zhao, S., Jiang, B., Wang, D., Qi, L., Wang, H., Chen, Z., Tu, J., Zhou, J., Li, M., Jin, J., & Tong, H. (2025). Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.018
Vancouver
Liu L, Gu J, Wang L, Maleki Goli M, Ghanad P, Xu H, et al. Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.10.018
BibTeX
@article{Liu2025,
author = {Liu, Lin and Gu, Jiayan and Wang, Lu and Maleki Goli, Maryam and Ghanad, Parnia and Xu, Huan and Zhao, Shuqi and Jiang, Bingqian and Wang, Dongmei and Qi, Lingling and Wang, Huanping and Chen, Zhimei and Tu, Jifang and Zhou, Junhao and Li, Mengyu and Jin, Jie and Tong, Hongyan},
title = {Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.10.018}
}
EUVIMED